Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...

Regeneron and Sanofi have collaborated on Dupixent since ... among other secondary endpoints. Dupixent, a fully human ...

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

While Regeneron doesn’t make vaccines specifically, its monoclonal antibody therapy provides a "passive vaccine" effect, temporarily protecting against infections. Dupixent Could Gain 30% More U ...

Regeneron Pharmaceuticals said the European ... an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have shown disease progression on the last therapy. The Tarrytown, N.Y ...

Sanofi and Regeneron’s blockbuster biologic Dupixent ... Dupixent, a fully human monoclonal antibody, inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways ...